IRF1 and cancer: We therefore set out to quantify to what extent the PD-L1 mRNA level (CD274) in cancer patients can be predicted by activity of the relevant TFs MYC, HIF1A/2A, JUN, IRF1, STAT1/3, NFKB, and NRF2.